Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Real-time Estimate Cboe BZX  -  03:37 2022-12-05 pm EST
4.405 USD   -1.01%
11/10Transcript : CorMedix Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
11/10CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating

08/12/2022 | 10:47am EST


ę MT Newswires 2022
All news about CORMEDIX INC.
11/10Transcript : CorMedix Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
11/10CorMedix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/10Cormedix : Q3 Earnings Snapshot
AQ
11/10Earnings Flash (CRMD) CORMEDIX Posts Q3 Revenue $6,817
MT
11/10CorMedix Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
AQ
11/10North American Morning Briefing: Crucial -3-
DJ
11/07CorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
AQ
11/02CorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Up..
AQ
10/21Cormedix Inc. : Changes in Registrant's Certifying Accountant, Financial Statements and Ex..
AQ
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,01 M - -
Net income 2022 -29,5 M - -
Net cash 2022 52,2 M - -
P/E ratio 2022 -6,10x
Yield 2022 -
Capitalization 184 M 184 M -
EV / Sales 2022 9 173x
EV / Sales 2023 27,5x
Nbr of Employees 30
Free-Float 98,7%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 4,45 $
Average target price 15,00 $
Spread / Average Target 237%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-2.20%184
MERCK KGAA-21.87%80 851
KYOWA KIRIN CO. LTD.-0.48%12 391
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD-30.86%4 623
SK BIOPHARMACEUTICALS CO., LTD.-25.41%4 353
YUHAN CORPORATION-6.12%3 045